1 October 2015
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
In accordance with Rule DTR 3.1.2, the Company was notified today that due to a change in personal circumstances Ian Page's total beneficial interest in the Company is now 705,701 shares, which represents 0.082% of the current issued share capital.
The reduction in his beneficial shareholding relates to a transfer to his now former spouse, Linda Page, which was announced on 25 November 2014.
For further information
Rob Lamb, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.